Discovery of diverse human BH3-only and non-native peptide binders of pro-apoptotic BAK indicate that activators and inhibitors use a similar binding mode and are not distinguished by binding affinity or kinetics

Fiona Aguilar, Stacey Yu, Robert A. Grant, Sebastian Swanson, Dia A. Ghose, Bonnie G. Su, Kristopher A. Sarosiek, Amy E. KeatingBiorxiv 2022 · DOI

TL;DR

This study reveals that both activators and inhibitors of the pro-apoptotic protein BAK bind to it using remarkably similar structural modes, affinities, and kinetics. This challenges previous assumptions and suggests that the subtle energetic differences in how these peptides interact with BAK's different conformational states, rather than distinct binding mechanisms, dictate their functional outcome.

What Problem Does This Paper Address?

Apoptosis, or programmed cell death, is crucial for maintaining tissue homeostasis, and its dysregulation is implicated in various diseases, including cancer and neurodegenerative disorders. The BCL-2 protein family plays a central role in controlling apoptosis, with pro-apoptotic members like BAK initiating the irreversible step of mitochondrial outer membrane permeabilization (MOMP). This process is triggered by the binding of BH3-only proteins to BAK, leading to its activation and subsequent oligomerization. However, it's not fully understood why some BH3-only proteins act as potent activators while others are inhibitors, or how these distinct functions arise from their interactions with BAK. This paper aims to unravel the sequence-function relationships governing BAK activation and inhibition by exploring a diverse range of peptide binders.

Methods

The researchers employed a multi-pronged approach:

  • Computational Protein Design (dTERMen): They used a computational method called dTERMen, which leverages statistical energies from known protein structures, to design novel peptide binders for BAK. This involved using the crystal structure of BAK bound to a known inhibitor as a template.
  • Yeast Surface-Display Screening: This technique was used to screen libraries of candidate BH3-like peptides for their ability to bind to BAK. They adapted a multi-valent format to enhance avidity for BAK.
  • Liposome Assays: These assays served as a proxy for MOMP. Liposomes mimicking the mitochondrial outer membrane were loaded with BAK and then incubated with peptides. Dye release from the liposomes indicated membrane permeabilization and thus BAK activation.
  • High-Resolution Crystal Structures: The team solved crystal structures of BAK bound to several novel peptides (both activators and inhibitors) to directly visualize their binding modes.
  • Bio-Layer Interferometry (BLI): This biophysical technique was used to systematically measure the binding affinities and kinetics (association and dissociation rates) of peptides to BAK.
  • Circular Dichroism (CD) Spectroscopy: Used to assess peptide helicity and potential self-association.
  • siRNA-treated Cell Assays: To investigate the function of identified peptides in a cellular context, they used permeabilized HeLa cells with specific BCL-2 family members knocked down to assess cytochrome c release.

Datasets

  • Human Proteome Sequences: The study utilized previously identified BH3-like sequences from the human proteome (DeBartolo et al., 2014) as candidates for binding to BAK.
  • Known Protein Structures: The dTERMen design method relies on a database of known protein structures.
  • Previously Solved BAK Structures: The researchers incorporated existing crystal structures of BAK in complex with various peptides (e.g., BIM-h3Glg, BIM-h3Pc-RT) for comparative analysis.

Key Insights and Ideas

  • Similar Binding Modes for Activators and Inhibitors: Perhaps the most striking finding is that both peptide activators and inhibitors of BAK bind to the protein using virtually identical structural modes, occupying the same hydrophobic groove. This challenges the intuitive notion that distinct binding mechanisms would differentiate their functions.
  • Affinity and Kinetics Aren't Deterministic: The study found no clear correlation between binding affinity or kinetics and whether a peptide acts as an activator or inhibitor. Some high-affinity binders were inhibitors, while others were activators, and vice-versa. This suggests that simple binding strength isn't the sole determinant of function.
  • Subtle Energetic Differences Matter: The authors propose a model where the key lies in the differential engagement of BAK's various conformational states. Activators likely bind preferentially to a transient, "activated" transition state, while inhibitors might stabilize the inactive monomeric state. This subtle energetic preference, rather than a fundamentally different binding site or mode, dictates the outcome.
  • Discovery of Novel Human Activators: The identification of BNIP5 and PXT1 as human BH3-only proteins that can activate BAK in cells is significant, expanding the known repertoire of endogenous BAK activators and suggesting potential roles in apoptotic regulation.
  • Non-natural Peptides as Potent Modulators: The computational design and screening efforts yielded novel non-native peptides that can act as potent activators or inhibitors, highlighting the potential for developing therapeutic agents targeting BAK.

Key Results

  • 19 Novel BAK Binders Identified: Through computational design and yeast surface display, the researchers identified 19 novel peptides that bind to BAK.
  • 5 Peptides Functioned as Inhibitors, 3 as Activators: Out of the tested peptides, five were found to inhibit BAK activity, and three functioned as activators, leading to liposome permeabilization.
  • BNIP5 and PXT1 Activate BAK in Cells: Two newly identified human peptides, BNIP5 and PXT1, were shown to induce cytochrome c release in cells, indicating BAK-dependent MOMP.
  • Structural Similarity: Crystal structures revealed that novel activators (like dM2) and inhibitors (like dF2, dF3) bind to BAK in the same groove and with similar peptide backbone conformations.
  • No Clear Distinction in Affinity/Kinetics: BLI experiments showed no consistent pattern where activators had weaker affinities or faster dissociation rates than inhibitors.

Limitations and Future Work

  • Model for Transition State: The exact structure of the BAK activation transition state remains unknown, and the proposed model relies on a hypothetical representation. Further structural studies of intermediate states would be beneficial.
  • In Vitro vs. In Vivo: While liposome assays and cell-based assays provide valuable insights, the complex cellular environment with numerous BCL-2 family members can influence peptide function.
  • Therapeutic Potential: The identified peptides, particularly the novel activators and potent inhibitors, hold promise for therapeutic development, but further in vivo studies are needed to assess their efficacy and safety.
  • Sequence-Function Relationship Nuances: While the study expanded the sequence space tested, the precise sequence features that dictate activator versus inhibitor function remain elusive, suggesting that subtle changes can have significant impacts. Future work could focus on systematically probing these sequence variations.
  • Role of Non-natural Amino Acids: The study utilized peptides with non-natural amino acids, and further investigation into their specific contributions to binding and function could be valuable.

Summary updated

Abstract

ABSTRACT Apoptosis is a programmed form of cell death important for the development and maintenance of tissue homeostasis. The BCL-2 protein family controls key steps in apoptosis, dysregulation of which can lead to a wide range of human diseases. BCL-2 proteins comprise three groups: anti-apoptotic proteins, pro-apoptotic proteins, and BH3-only proteins. BAK is one of two pro-apoptotic proteins, and previous work has shown that binding of certain BH3-only proteins such as truncated BID (tBID), BIM, or PUMA to BAK leads to mitochondrial outer membrane permeabilization, the release of cytochrome c, and ultimately cell death. This process, referred to as activation , involves the BH3-stimulated conversion of BAK from monomer to dimer and then to oligomers that promote membrane disruption. Crystal structures of putative intermediates in this pathway, crosslinking data, and in vitro functional tests have provided insights into the activation event, yet the sequence-function relationships that make some but not all BH3-only proteins function as activators remain largely unexamined. In this work, we used computational protein design, yeast surface-display screening of candidate BH3-like peptides, and structure-based energy scoring to identify ten new binders of BAK that span a large sequence space. Among the new binders are two peptides from human proteins BNIP5 and PXT1 that promote BAK activation in liposome assays and induce cytochrome-c release from mitochondria, expanding current views of how BAK-mediated cell death may be triggered in cells. High-resolution crystal structures and binding experiments revealed a high degree of similarity in binding geometry, affinity, and association kinetics between peptide activators and inhibitors, including peptides described previously and those identified in this work. We propose a model for BAK activation that is based on differential engagement of BAK monomers vs. the BAK activation transition state that integrates our observations with previous reports of BAK binders, activators, and inhibitors.
BibTeX
@misc{aguilar2022discovery,
  author = {Fiona Aguilar and Stacey Yu and Robert A. Grant and Sebastian Swanson and Dia A. Ghose and Bonnie G. Su and Kristopher A. Sarosiek and Amy E. Keating},
  title = {{Discovery of diverse human BH3-only and non-native peptide binders of pro-apoptotic BAK indicate that activators and inhibitors use a similar binding mode and are not distinguished by binding affinity or kinetics}},
  year = {2022},
  doi = {10.1101/2022.05.07.491048},
  howpublished = {Biorxiv},
}
Figure